Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
Commentary|Videos|February 25, 2026

Fragmentation Remains the Biggest Data Risk

Jonathan Andrus, co-CEO of CRIO, outlines how disconnected systems and inconsistent data collection across sites create risk, while centralized eSource approaches present a major opportunity.

In a recent video interview with Applied Clinical Trials, Jonathan Andrus, co-CEO of CRIO, discussed how 2026 is expected to mark a continued shift toward site-based technologies and protocol-driven eSource to improve data quality, compliance, and trial efficiency. He emphasized the importance of capturing high-quality data at the point of patient encounter, reducing fragmentation across sites, and enabling real-time data access and monitoring. Andrus also highlighted the growing need for cross-functional collaboration during protocol design, stronger governance across the data lifecycle, and increased use of AI to streamline study build, data review, and operational workflows.

Editor's note: This transcript is a lightly edited rendering of the original audio/video content. It may contain errors, informal language, or omissions as spoken in the original recording.

ACT: From a data management perspective, where do you see the biggest risk—and opportunity—for clinical trials this year?

Andrus: The biggest risk is fragmented, disconnected data collection across sites. If you think about a large phase 3 trial with 150 sites, each site may be collecting data differently—paper, EHR, hybrid approaches—creating significant variability in how data originate.

From a clinical data management perspective, that inconsistency creates downstream challenges in data quality, reconciliation, and efficiency.

The opportunity is the opposite of that: purpose-built eSource systems that reduce fragmentation and minimize transcription. When sites can document research activities once in a system designed specifically for clinical research, you eliminate a major source of data discrepancies and delays.

It also enables remote monitoring and verification, improves CRO resource utilization, and allows teams to identify data issues much earlier—at the point of capture rather than after data entry into EDC systems. That shift has a significant impact on both efficiency and data quality.


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.